Wellington Biomedical Innovation Master Investors (Cayman) I L.P. - Sep 12, 2024 Form 3 Insider Report for Zenas BioPharma, Inc. (ZBIO)

Role
10%+ Owner
Signature
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. By: Wellington Management Company LLP, as Investment Adviser By: /s/ Jennifer C. Boylan, Authorized Signatory
Stock symbol
ZBIO
Transactions as of
Sep 12, 2024
Transactions value $
$0
Form type
3
Date filed
9/12/2024, 09:45 PM
Previous filing
Jul 22, 2024
Next filing
Sep 18, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ZBIO Series A Convertible Preferred Stock Sep 12, 2024 Common Stock 181K Direct F1
holding ZBIO Series B Convertible Preferred Stock Sep 12, 2024 Common Stock 420K Direct F2
holding ZBIO Series C Convertible Preferred Stock Sep 12, 2024 Common Stock 201K Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series A Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 8.6831-for-1 basis and has no expiration date. The Series A Convertible Preferred Stock will automatically convert into common stock upon the closing of the Company's initial public offering.
F2 Each share of Series B Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 8.6831-for-1 basis and has no expiration date. The Series B Convertible Preferred Stock will automatically convert into common stock upon the closing of the Company's initial public offering.
F3 Each share of Series C Convertible Preferred Stock is convertible into shares of the Issuer's Common Stock on a 8.6831-for-1 basis and has no expiration date. The Series C Convertible Preferred Stock will automatically convert into common stock upon the closing of the Company's initial public offering.